Trial site
National Multidisciplinary Transport Hospital Tsar Boris III
- 14running trials
- 7closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Conditions
- Heart failure7 trials
- COPD4 trials
- Atrial fibrillation3 trials
- Obesity3 trials
- Stroke3 trials
- Ulcerative colitis2 trials
- Asthma1 trial
- Coronary artery disease1 trial
- Deep vein thrombosis and pulmonary embolism1 trial
- Familial hypercholesterolaemia1 trial
- Phase
- Phase 314 trials
- Phase 26 trials
- Phase 41 trial
- Status
- Completed7 trials
- Recruiting6 trials
- Active, not recruiting5 trials
- Not yet recruiting3 trials
- Lead sponsor
- Chiesi Farmaceutici S.p.A.3 trials
- Amgen Inc.2 trials
- Boehringer Ingelheim2 trials
- Novartis Pharma AG2 trials
- Novo Nordisk A/S2 trials
- and 8 more
Running trials
Not yet recruiting
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Heart failure4 recruiting
- Atrial fibrillation2 recruiting
- Obesity2 recruiting
- Stroke2 recruiting
- Ulcerative colitis2 recruiting
- Deep vein thrombosis and pulmonary embolism1 recruiting
Closed trials
Completed
Completed
A proof of concept and dose-finding study of XXB750 in patients with heart failure
Completed
Completed
Completed
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy
Completed
Completed
Site data: EU CTIS (euclinicaltrials.eu)Updated 18 Nov 2026